Overview

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Status:
RECRUITING

Trial end date:
2034-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.

Phase:

PHASE2

Details

Lead Sponsor:

Ashish Shah

Collaborators:

Denovo Biopharma LLC
National Cancer Institute (NCI)

Treatments:

Flucytosine